The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antitumor activities of bevacizumab for KRAS, BRAF, and PIK3CA mutated human colorectal cancer xenograft models.
Suguru Harada
No relevant relationships to disclose
Mieko Yanagisawa
No relevant relationships to disclose
Toshiki Iwai
No relevant relationships to disclose
Satoshi Aida
No relevant relationships to disclose
Mitsue Kurasawa
No relevant relationships to disclose
Keigo Yorozu
No relevant relationships to disclose
Kaname Yamamoto
No relevant relationships to disclose
Naoki Harada
No relevant relationships to disclose